Article
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study.
Investigational new drugs - 1 Apr 2023
Yang James Chih-Hsin, Su Wu-Chou, Chiu Chao-Hua, Shiah Her-Shyong, Lee Kang-Yun, Hsia Te-Chun, Uno Makiko, Crawford Nigel, Terakawa Hiroshi, Chen Wen-Chi, Takayama Gensuke, Hsu Ching, Hong Ying, Saintilien Carline, McGill Joseph, Chang Gee-Chen
Abstract excerpt
The objective of this study was to evaluate the safety and tolerability of DS-1205c, an oral AXL-receptor inhibitor, in combination with osimertinib in metastatic or unresectable EFGR-mutant non-small cell lung cancer (NSCLC) patients who developed disease progression during EGFR tyrosine kinase inhibitor (TKI) treatment. An open-label, non-randomized phase 1 study was conducted in Taiwan, in which 13 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.